Acidic Leucine-Rich Nuclear Protein Phosphatase 32B Promotes Prostate Adenocarcinoma Cell Progression by Regulating Apoptosis and Epithelial-Mesenchymal Transition.

IF 1.9 4区医学 Q3 INTEGRATIVE & COMPLEMENTARY MEDICINE

Alternative therapies in health and medicine Pub Date : 2024-10-01

Min A, Lei Wang, Yonghao Xue, Chaoqi Wang

{"title":"Acidic Leucine-Rich Nuclear Protein Phosphatase 32B Promotes Prostate Adenocarcinoma Cell Progression by Regulating Apoptosis and Epithelial-Mesenchymal Transition.","authors":"Min A, Lei Wang, Yonghao Xue, Chaoqi Wang","doi":"","DOIUrl":null,"url":null,"abstract":"Objective: This work aimed to investigate the expression of acidic leucine-rich nuclear protein phosphatase 32B (ANP32B) in prostate adenocarcinoma (PRAD) and evaluate the effect of ANP32B on the proliferation of prostate adenocarcinoma cells.Methods: We evaluated the expression of ANP32B in PRAD tissues and cells compared to the controls obtained from The Cancer Genome Atlas (TCGA). siRNA targeting ANP32B was transfected into DU145 cells to knockdown the ANP32B expression and plasmids carrying ANP32B coding region were used to overexpress ANP32B in PC3 cells. We analyze the knockdown or overexpression efficiency of ANP32B with quantitative reverse-transcription PCR (RT-qPCR) and Western blot. CCK-8 assay, cell colony formation assay, transwell assay, and EdU labeling were performed to investigate the function of ANP32B on the progression of PRAD. Finally, the expression of the cell cycle marker, apoptosis marker, and epithelial-mesenchymal transition (EMT) marker were detected by Western blot.Results: ANP32B expression was upregulated in PRAD samples compared to normal samples. Exogenous ANP32B overexpression promoted cell viability, cell colony formation, 5-ethynyl-2'-deoxyuridine (EdU) incorporation, and cell migration. Inhibition of ANP32B suppressed cell proliferation, growth, and migration. At the molecular level, the genes promoting cell growth and migration, including cyclin D1 and N-cadherin, were significantly upregulated after ANP32B overexpression, whereas those inhibiting cell growth and migration such as cleaved caspase 3 and E-cadherin were downregulated.Conclusion: The tumor-promoting function of ANP32B can be attributed to its capacity to facilitate cell progression, and it may be considered as a therapeutic marker for PRAD therapy.","PeriodicalId":7571,"journal":{"name":"Alternative therapies in health and medicine","volume":" ","pages":"454-459"},"PeriodicalIF":1.9000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alternative therapies in health and medicine","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INTEGRATIVE & COMPLEMENTARY MEDICINE","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: This work aimed to investigate the expression of acidic leucine-rich nuclear protein phosphatase 32B (ANP32B) in prostate adenocarcinoma (PRAD) and evaluate the effect of ANP32B on the proliferation of prostate adenocarcinoma cells.

Methods: We evaluated the expression of ANP32B in PRAD tissues and cells compared to the controls obtained from The Cancer Genome Atlas (TCGA). siRNA targeting ANP32B was transfected into DU145 cells to knockdown the ANP32B expression and plasmids carrying ANP32B coding region were used to overexpress ANP32B in PC3 cells. We analyze the knockdown or overexpression efficiency of ANP32B with quantitative reverse-transcription PCR (RT-qPCR) and Western blot. CCK-8 assay, cell colony formation assay, transwell assay, and EdU labeling were performed to investigate the function of ANP32B on the progression of PRAD. Finally, the expression of the cell cycle marker, apoptosis marker, and epithelial-mesenchymal transition (EMT) marker were detected by Western blot.

Results: ANP32B expression was upregulated in PRAD samples compared to normal samples. Exogenous ANP32B overexpression promoted cell viability, cell colony formation, 5-ethynyl-2'-deoxyuridine (EdU) incorporation, and cell migration. Inhibition of ANP32B suppressed cell proliferation, growth, and migration. At the molecular level, the genes promoting cell growth and migration, including cyclin D1 and N-cadherin, were significantly upregulated after ANP32B overexpression, whereas those inhibiting cell growth and migration such as cleaved caspase 3 and E-cadherin were downregulated.

Conclusion: The tumor-promoting function of ANP32B can be attributed to its capacity to facilitate cell progression, and it may be considered as a therapeutic marker for PRAD therapy.

本刊更多论文

酸性富亮氨酸核蛋白磷酸酶 32B 通过调控细胞凋亡和上皮-间质转化促进前列腺癌细胞进展

研究目的本研究旨在调查酸性富亮氨酸核蛋白磷酸酶32B（ANP32B）在前列腺癌（PRAD）中的表达，并评估ANP32B对前列腺癌细胞增殖的影响：将靶向ANP32B的siRNA转染至DU145细胞以敲除ANP32B的表达，并使用携带ANP32B编码区的质粒在PC3细胞中过表达ANP32B。我们通过逆转录定量 PCR（RT-qPCR）和 Western 印迹来分析 ANP32B 的敲除或过表达效率。通过CCK-8检测、细胞集落形成检测、Transwell检测和EdU标记来研究ANP32B对PRAD进展的作用。最后，通过 Western blot 检测细胞周期标志物、细胞凋亡标志物和上皮-间质转化（EMT）标志物的表达：结果：与正常样本相比，ANP32B在PRAD样本中表达上调。外源性ANP32B过表达可促进细胞活力、细胞集落形成、5-乙炔基-2'-脱氧尿苷（EdU）掺入和细胞迁移。抑制 ANP32B 可抑制细胞增殖、生长和迁移。在分子水平上，ANP32B过表达后，促进细胞生长和迁移的基因（包括细胞周期蛋白D1和N-cadherin）显著上调，而抑制细胞生长和迁移的基因（如裂解的caspase 3和E-cadherin）则下调：结论：ANP32B的肿瘤促进功能可归因于其促进细胞进展的能力，它可被视为PRAD治疗的治疗标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Alternative therapies in health and medicine INTEGRATIVE & COMPLEMENTARY MEDICINE-

CiteScore

0.90

自引率

0.00%

发文量

219

期刊介绍： Launched in 1995, Alternative Therapies in Health and Medicine has a mission to promote the art and science of integrative medicine and a responsibility to improve public health. We strive to maintain the highest standards of ethical medical journalism independent of special interests that is timely, accurate, and a pleasure to read. We publish original, peer-reviewed scientific articles that provide health care providers with continuing education to promote health, prevent illness, and treat disease. Alternative Therapies in Health and Medicine was the first journal in this field to be indexed in the National Library of Medicine. In 2006, 2007, and 2008, ATHM had the highest impact factor ranking of any independently published peer-reviewed CAM journal in the United States—meaning that its research articles were cited more frequently than any other journal’s in the field. Alternative Therapies in Health and Medicine does not endorse any particular system or method but promotes the evaluation and appropriate use of all effective therapeutic approaches. Each issue contains a variety of disciplined inquiry methods, from case reports to original scientific research to systematic reviews. The editors encourage the integration of evidence-based emerging therapies with conventional medical practices by licensed health care providers in a way that promotes a comprehensive approach to health care that is focused on wellness, prevention, and healing. Alternative Therapies in Health and Medicine hopes to inform all licensed health care practitioners about developments in fields other than their own and to foster an ongoing debate about the scientific, clinical, historical, legal, political, and cultural issues that affect all of health care.